Citations

Institution: Mayo Clinic Clear

Showing 10 of 108152 citations.

ERβ Expression and Breast Cancer Risk Prediction for Women with Atypias
Carter, Jodi M. , Hawse, John R. , Bois, Melanie C. , Frost, Marlene H., Hartmann, Lynn C. , Visscher, Daniel W., Hoskin, Tanya L. , Bois, Melanie, Frost, Marlene, Radisky, Derek C. , Hieken, Tina J. , Degnim, Amy C. , Carter, Jodi

Cancer Prevention Research | August 14, 2015 | Volume: 8 | Issue: 11 | Pages: 1084-1092

10.1158/1940-6207.capr-15-0198 | PMID 26276747 Get It

Abstract Estrogen receptor (ER) β is highly expressed in normal breast epithelium and a putative tumor suppressor. Atypical hyperplasia substantially increases breast cancer risk, but identification of biomarkers to further improve risk stratification is needed. We evaluated ERβ expression in breast tissues from women with atypical hyperplasia and association with subsequent breast cancer risk. ERβ expression was examined by immunohistochemistry in a well-characterized 171-women cohort with atypical hyperplasia diagnosed 1967–1991. Nuclear ERβ percent and intensity was scored in the atypia and adjacent normal lobules. An ERβ sum score (percent + intensity) was calculated and grouped as low, moderate, or high. Competing risks regression was used to assess associations of ERβ expression with breast cancer risk. After 15-year median follow-up, 36 women developed breast cancer. ERβ expression was lower in atypia lobules in than normal lobules, by percent staining and intensity (both P < 0.001). Higher ERβ expression in the atypia or normal lobules, evaluated by percent staining, intensity or sum score, decreased the risk of subsequent breast cancer by 2-fold (P = 0.04) and 2.5-fold (P = 0.006). High normal lobule ERβ expression conferred the strongest protective effect in premenopausal women: the 20-year cumulative incidence of breast cancer was 0% for women younger than 45 years with high versus 31% for low–moderate ERβ expression (P = 0.0008). High ERβ expression was associated with a significantly decreased risk of breast cancer in women with atypical hyperplasia. These data suggest that ERβ may be a useful biomarker for risk stratification and a novel therapeutic target for breast cancer risk reduction. Cancer Prev Res; 8(11); 1084–92. ©2015 AACR.
Effect of vitamin D3 treatment on endothelial function in obese adolescents
Javed, Asma , Balagopal, Prabhakaran , Kumar, Seema , Kullo, Iftikhar J.

Pediatric Obesity | August 14, 2015 | Volume: 11 | Issue: 4 | Pages: 279-284

10.1111/ijpo.12059 | PMID 26273791 Get It

SummaryBackgroundObesity in children is associated with vitamin D deficiency and endothelial dysfunction. It is not known if treatment with vitamin D improves endothelial function in obese adolescents.ObjectiveThis study aimed to determine whether treatment with vitamin D3 improves endothelial function in obese adolescents.MethodsNineteen obese adolescents, 13–18 years of age, with 25‐hydroxy vitamin D (25[OH]D) levels <75 nmol L−1 were treated with 100 000 IU vitamin D3 orally once a month for 3 months in an open‐label, single‐centre prospective trial. Endothelial function was assessed by flow‐mediated dilatation (FMD) of the brachial artery at study entry and 1 month after the third dose of vitamin D3. Biochemical parameters, including calcium, fasting lipids, glucose, insulin and high‐sensitivity C‐reactive protein, were also obtained.ResultsMean 25(OH)D levels increased from 55.9 ± 12.2 to 86.9 ± 16.7 nmol L−1 (P < 0.01). There was no correlation between 25(OH)D levels and brachial artery FMD. The brachial artery FMD (%) did not change significantly following vitamin D3 treatment (9.5 ± 3.53 vs. 10.3 ± 3.83, P = 0.83). Serum parathyroid hormone declined from 3.8 ± 1.5 to 3.1 ± 1 pmol L−1 (P = 0.01). The remainder of biochemical measurements did not show a significant change.ConclusionsTreatment with vitamin D3, 100 000 IU once a month for 3 months was effective in increasing 25(OH)D levels in obese adolescents but did not impact endothelial function.
Patient-Reported Functional and Quality of Life Outcomes in a Large Cohort of Long-Term Survivors of Ewing Sarcoma
Stish, Bradley J. , Rose, Peter S. , Arndt, Carola A.S., Ahmed, Safia K. , Arndt, Carola A., Laack, Nadia N. , Stish, Bradley J

Pediatric Blood & Cancer | August 14, 2015 | Volume: 62 | Issue: 12 | Pages: 2189-2196

10.1002/pbc.25710 | PMID 26275239 Get It

Report of the ASFA apheresis registry study on Wilson's disease
Pham, Huy P. , Cooling, Laura , Hofmann, Jan , Kim, Haewon C., Morgan, Shanna, Schneiderman, Jennifer , Wong, Edward C.C. , Wu, Yanyun , Winters, Jeffrey L. , Schwartz, Joseph E. , Pagano, Monica B. , Yamada, Chisa , Pham, Huy P

Journal of Clinical Apheresis | August 14, 2015 | Volume: 31 | Issue: 1 | Pages: 11-15

10.1002/jca.21396 | PMID 26275240 Get It

PurposeWilson's disease is a rare autosomal recessive genetic disorder that results in accumulation of copper in the liver, brain, cornea and kidney. Therapeutic plasma exchange (TPE) has been used to remove copper and provide a bridge to liver transplantation. We report here the collective experiences through the ASFA apheresis registry on Wilson's disease.MethodsThe ASFA apheresis registry is a multi‐center registry study. Both prospective and retrospective data, with the latter involving data collection back to January 2000 are entered in the registry. The registry includes patient demographics, apheresis procedural information, treatment schedules, and treatment outcomes and complications.ResultsA total of 10 patients (3 males and 7 females) with Wilson's disease treated between 2005 and 2013 were included. Median age of first diagnosis and first TPE were 16 and 17 years, respectively. Via central venous access, these patients underwent a total of 43 TPEs; the median number of TPE procedures per patient was 3.5. All of the TPEs used ACD‐A as anticoagulation, 42/43 TPEs targeted 1–1.25 plasma volumes, and 41/43 TPEs were performed with 100% fluid balance. Post TPE procedures, 9 patients underwent liver transplantation; all 10 patients had at least a 6‐month survival.ConclusionsAll 10 patients with Wilson's disease who underwent TPE had a positive outcome in terms of 6‐month survival. In this first report of the ASFA apheresis registry study, we have demonstrated the value of using this registry to collect apheresis‐related patient outcomes from multiple centers. J. Clin. Apheresis 31:11–15, 2016. © 2015 Wiley Periodicals, Inc.
Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease
Rammo, Richard , Rock, Adam , Transou, Andrea, Raghunathan, Aditya , Rock, Jack , Raghunathan, Aditya

Journal of Neurosurgery | August 14, 2015 | Volume: 124 | Issue: 2 | Pages: 496-500

10.3171/2015.1.jns142260 | PMID 26274993 Get It

Meningiomas are common intracranial tumors categorized as Grades I–III per the current WHO guidelines. A small percentage of meningiomas are Grades II and III, which are likely to recur after initial treatment. Grade III meningiomas are considered to be malignant and warrant aggressive management. If surgery and radiation fail to produce lasting remission, effective treatment options for patients with progressive anaplastic meningiomas are elusive. The authors present the case of a patient with a meningioma that gradually progressed from Grade I to Grade III over 12 years despite repeated surgery and radiation therapy. The patient has been in remission for over 3 years following octreotide therapy.
Morphologically Occult Systemic Mastocytosis in Bone Marrow
Reichard, Kaaren K. , Chen, Dong , Pardanani, Animesh , McClure, Rebecca F., Howard, Matthew T., Kurtin, Paul J. , Wood, Adam J. , Ketterling, Rhett P. , King, Rebecca L. , He, Rong, Morice, William G. , Hanson, Curtis A. , Morice, William George , Chen, Dong , Ketterling, Rhett P

American Journal of Clinical Pathology | August 14, 2015 | Volume: 144 | Issue: 3 | Pages: 493-502

10.1309/ajcpsgq71gjqqacl | PMID 26276780 Get It

Validation of a gastric cancer nomogram using a cancer registry
Kidwell, John T. , McGhan, Lee J., Dueck, Amylou C. , Pockaj, Barbara A. , Gray, Richard J. , Wasif, Nabil , Ashfaq, Awais , Dueck, A. C. , Ashfaq, Awais , Bagaria, Sanjay P.

Journal of Surgical Oncology | August 14, 2015 | Volume: 112 | Issue: 4 | Pages: 377-380

10.1002/jso.23999 | PMID 26271201 Get It

BackgroundA Memorial Sloan Kettering (MSKCC) nomogram predicts disease specific survival (DSS) for gastric adenocarcinoma. The goal of this study is to use a cancer registry to compare nomogram predicted survival with actual survival in the general population.MethodsAll patients undergoing surgery for gastric adenocarcinoma from the Surveillance, Epidemiology, and End Results (SEER) database (1988–2012) were studied.Results6954 patients were identified. Majority of cancers were in the antrum (30.2%), and had intestinal histology (73.7%). Median follow‐up was 8.2 years. Five year DSS for nomogram risk groups (0–25%, 26–50%, 51–75%, and 76–100%) was 23%, 48%, 57%, and 81% respectively. Actual DSS was 7–15% lower than nomogram predicted DSS. Relative to patients in the 76–100% 5‐year DSS risk group, patients in the 0–25%, 26–50%, and 51–75% groups had significantly higher risks of death with hazard ratios of 6.84 (95%CI 6.12–7.65), 3.30 (95%CI 2.83–3.86), and 2.64 (95%CI 2.30–3.03), respectively (all P < 0.001). The concordance index for 5‐year nomogram predicted DSS was 0.68 (95%CI 0.67–0.69).ConclusionsThe MSKCC gastric cancer nomogram over‐estimates DSS from gastric cancer in the general population and has a moderate concordance index. Predictive tools generated at specialized institutions may not perform as well in the general population. J. Surg. Oncol. 2015; 112:377–380. © 2015 Wiley Periodicals, Inc.
Anesthesia and Poliomyelitis: A Matched Cohort Study
Alstine, Luke W. Van, Gunn, Paul W., Schroeder, Darrell R. , Hanson, Andrew C. , Sorenson, Eric J. , Martin, David P. , Van Alstine, Luke W, Schroeder, Darrell

Anesthesia & Analgesia | August 14, 2015 | Volume: 122 | Issue: 6 | Pages: 1894-1900

10.1213/ane.0000000000000924 | PMID 26273744 Get It

BACKGROUND: Poliomyelitis is a viral infectious disease caused by 1 of the 3 strains of poliovirus. The World Health Organization launched an eradication campaign in 1988. Although the number of cases of poliomyelitis has drastically declined, eradication has not yet been achieved, and there are a substantial number of survivors of the disease. Survivors of poliomyelitis present a unique set of challenges to the anesthesiologist. The scientific literature regarding the anesthetic management of survivors of poliomyelitis, however, is limited and primarily experiential in nature. Using a retrospective, matched cohort study, we sought to more precisely characterize the anesthetic implications of poliomyelitis and to determine what risks, if any, may be present for patients with a history of the disease. METHODS: Using the Mayo Clinic Life Sciences System Data Discovery and Query Builder, study subjects were identified as those with a history of paralytic poliomyelitis who had undergone major surgery at Mayo Clinic Rochester between 2005 and 2009. For each case, 2 sex- and age-matched controls that underwent the same surgical procedure during the study period were randomly selected from a pool of possible controls. Medical records were manually interrogated with respect to demographic variables, comorbid conditions, operative and anesthetic course, and postoperative course. RESULTS: We analyzed 100 cases with 2:1 matched controls and found that the peri- and postoperative courses were very similar for both groups of patients. Pain scores, postanesthesia care unit admission, length of postanesthesia care unit stay, intensive care unit admission, length of intensive care unit stay, and initial extubation location were not significantly different between the 2 groups. Looking at pulmonary complications in our primary outcome, there was no significant difference between the 2 groups (17% vs 14% for polio versus control, respectively; conditional logistic regression odds ratio = 1.5; 95% confidence interval, 0.7–3.3; P = 0.33). In addition, no difference was noted in those requiring a code or rapid response team intervention (4% vs 3% for polio versus control; P = 0.46) and the 30-day mortality rate was also not significantly different, with 2% of polio patients dying compared with 3% of controls ( P = 0.79). The analysis of the primary outcome was repeated for the subset of patients with a history of poliomyelitis who had persistent neurologic deficits preoperatively ( n = 36) and their matched controls ( n = 72). In this subset analysis, there were 4 (11%) polio patients and 8 (11%) control patients who experienced pulmonary complications (conditional logistic regression odds ratio = 1.00; 95% confidence interval, 0.27–3.72; P = 1.00). The percentage of patients experiencing specific pulmonary complications of interest was similar between groups (postoperative mechanical ventilation: 6% vs 8% for polio and control patients, respectively; prolonged mechanical ventilation: 0% vs 1%; reintubation: 8% vs 4%; pulmonary infection: 6% vs 6%; and aspiration: 0% vs 1%). CONCLUSIONS: This study suggests that patients with a history of poliomyelitis do not seem to have an increased risk of pulmonary complications in the perioperative period. However, an odds ratio as great as 3.3-fold may be present.
Imaging approach to measuring small bowel motility
Camilleri, Michael

American Journal of Physiology-Gastrointestinal and Liver Physiology | August 14, 2015 | Volume: 309 | Issue: 6 | Pages: G411-G412

10.1152/ajpgi.00265.2015 | PMID 26272261 Get It